In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ODYSSEY FHI & II - Investigational alirocumab shows lipid-lowering promise

Hot Line II: Coronary artery disease and lipids

Prevention


BARCELONA, Spain – Sunday 31 August: An investigational lipid-lowering agent called alirocumab produced superior results compared to placebo in Hot Line studies reported today at ESC Congress 2014.
Alirocumab, is a fully‐human monoclonal antibody and part of a new class of cholesterol-lowering drugs known as PCSK9 (proprotein convertase subtilisin / kexin type 9) inhibitors.
ODYSSEY FH I & II were two studies that  evaluated the effect of alirocumab in patients with heterozygous familial hypercholesterolaemia whose low‐density lipoprotein‐cholesterol (LDL‐C) levels were inadequately controlled by their current statin and other lipid-lowering therapy (LLT).
Heterozygous familial hypercholesterolaemia (heFH) is a common inherited disease which causes extremely high levels of LDL-C and increased risk of premature atherosclerosis and cardiovascular disease, explained principal investigator Michel Farnier, MD, PhD, from Point Médical, Dijon, France.
“Patients with heFH are difficult to treat in clinical practice. The actual recommended treatment for this category of patients is a statin at the maximum tolerated dose (mainly atorvastatin or rosuvastatin) and if necessary, combination with other lipid-lowering drugs. However, even at this maximum tolerated treatment, their baseline levels of LDL-C in our studies were relatively high (mean around 3.5 and 3.7mmol/l),” he said.

The double-blind, placebo-controlled trials, conducted in North America, Europe and South Africa, together included a total of 735 heFH patients (aged approximately 52-53 years) who were randomised to receive either a subcutaneous injection of alirocumab 75-150 mg every 2 weeks (n=490 across both studies), or matching placebo (n=245 across both studies) for 78 weeks, in addition to their current therapy.
“It is important to emphasize that in both trials, patients were very well treated before the trial,” noted Dr. Farnier. All of them were on statins, with more than 80% on maximum doses, and 55-65% on combination therapy with ezetimibe.”

At week 24, alirocumab significantly reduced LDL-C from baseline (mean
48.8% and 48.7% in the ODYSSEY FH I & II studies respectively) compared to increases of 9.1% and 2.8% respectively seen in the placebo-treated arms (P<0.0001). To reach a pre-specified LDL-C level below 1.81 mmol/l (70 mg/dl), an up-titration to 150 mg every 2 weeks was necessary in only about 40 % of patients receiving alirocumab treatment.
Similarly, by week 24, significantly more alirocumab-treated patients compared to those on placebo had reached the LDL-C goal of a level below 2.59 mmol/L (100 mg/dL) in high-risk patients or below 1.81 mmol/L (70 mg/dL) in very high-risk patients (72.2% vs 2.4% in FHI, and 81.4% vs 11.3%; both P<0.0001).
Pooled data from the two studies shows treatment-emergent adverse events occurred in a similar proportion of patients on alirocumab and placebo (74.8% vs 75.4%), leading to study discontinuation in 3.1% and 3.7% patients, respectively.

“Previous studies have shown that only about 20% of heFH patients are able to reach a goal of less than 2.5mmol/l.” noted Dr. Farnier. “Due to the dramatic complementary decrease in LDL-C that our studies obtained with alirocumab, this new strategy is particularly important for this category of patients at high risk of cardiovascular disease.”

Notes to editor

SOURCES OF FUNDING: The studies were funded by Sanofi/Regeneron.
DISCLOSURES: Dr. Farnier disclosed grants, consulting fees and/or honoraria and delivering lectures for Abbott, Amgen, Boehringer- Ingelheim, Eli Lilly Genzyme, Kowa, Merck and Co, Novartis, Pfizer, Recordati, Roche, Sanofi-Regeneron, and SMB.
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2014
The ESC Congress is currently the world's largest international congress in cardiovascular medicine.  The spotlight of this year's event is “innovation and the heart”.  ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.